Genomics-Driven Drug Trials Built To Be Fast And Flexible
This article was originally published in The Gray Sheet
Pioneering next-generation sequencing enrollment strategies are coupled with adaptive statistical designs in the next wave of drug "basket" trials from NCI, ASCO and Novartis.
You may also be interested in...
Roche may be behind Merck and Bristol in the PD-L1/PD-1 immune checkpoint inhibitor race, but its patient plans for atezolizumab are starting to demonstrate the power of the company's strategy of combining "comprehensive diagnostics" and a broad pipeline to establish a dominant position in immuno-oncology.
Sponsors say the large number of biomarkers that will be searched for in candidates for the lung cancer trial should allow researchers to find patients much faster, and will offer cost-savings over traditional drug development.
The other seven drugs on the initial list for negotiation are already heavily rebated and CMS could choose not to go much lower than current net prices, SSR Health report points out.